It should underline that elderly men with metastatic CRPC cannot tolerate chemotherapy-induced toxicities such as neutropenia, anemia, and mucositis[34] and to avoid this last adverse event in men aged >75 years, a prophylactic use of G-CSF, especially at cycle 1 could be undertaken. The gene discussed is CSF3; the disease is Decreased total neutrophil count.